Effect of Coexisting KRAS and TP53 Mutations in Patients Treated With Chemotherapy for Non-small-cell Lung Cancer

被引:20
作者
Tomasini, Pascale [1 ,2 ,3 ]
Mascaux, Celine [1 ,2 ,3 ]
Jao, Kevin [1 ,2 ]
Labbe, Catherine [1 ,2 ]
Kamel-Reid, Suzanne [4 ,5 ]
Stockley, Tracy [4 ,5 ]
Hwang, David M. [4 ,5 ]
Leighl, Natasha B. [1 ,2 ]
Liu, Geoffrey [1 ,2 ]
Bradbury, Penelope A. [1 ,2 ]
Pintilie, Melania [6 ]
Tsao, Ming-Sound [4 ,5 ]
Shepherd, Frances A. [1 ,2 ]
机构
[1] Univ Toronto, Univ Hlth Network, Princess Margaret Canc Ctr, Div Med Oncol & Hematol, Toronto, ON, Canada
[2] Univ Toronto, Dept Med, Toronto, ON, Canada
[3] Aix Marseille Univ, AP HM, Multidisciplinary Oncol & Therapeut Innovat Dept, Marseille, France
[4] Univ Toronto, Dept Pathol, Univ Hlth Network, Toronto, ON, Canada
[5] Univ Toronto, Dept Lab Med & Pathobiol, Toronto, ON, Canada
[6] Princess Margaret Canc Ctr, Dept Biostat, Toronto, ON, Canada
关键词
Chemotherapy; Coexisting mutations; KRAS; Lung cancer; TP53; SOMATIC MUTATIONS; POOLED ANALYSIS; OPEN-LABEL; EGFR; P53; THERAPY; TRIALS; ADENOCARCINOMA; MULTICENTER; CRIZOTINIB;
D O I
10.1016/j.cllc.2018.12.009
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
The LACE-Bio group found adjuvant chemotherapy to be deleterious in non small-cell lung cancer with coexisting KRAS/TP53 mutations. We analyzed 218 patients with non small-cell lung cancer (28 with coexisting KRAS/TP53 mutations, 77 with TP53 mutations, 37 with KRAS mutations, and 76 with no KRAS/TP53 mutations) who received chemotherapy. There was no difference in disease-free or progression-free survival between the 4 groups. Overall survival was longer in the no KRAS/TP53 group. Background: KRAS and TP53 are common mutations in non-small-cell lung cancer (NSCLC). The Lung Adjuvant Cisplatin Evaluation Biological Program group found adjuvant chemotherapy to be deleterious in patients with coexisting KRAS/TP53 mutations. Patients and Methods: To validate these results, patients with NSCLC tested for KRAS and TP53 mutations and receiving chemotherapy for any stage NSCLC were selected. Mutation status was analyzed using next generation sequencing (Illumina) or multiplex recurrent mutation detection (MassARRAY, Agena Biosciences) assays, and was correlated with clinical and demographic data. Disease-free (DFS) or progression-free survival (PFS) was the main endpoint, and overall survival (OS) was the secondary endpoint. Results: Among 218 patients, 28 had coexisting KRAS/TP53 mutations, 77 TP53, 37 KRAS, 76 had neither KRAS nor TP53 mutation (WT/WT). There was no DFS/PFS difference for the KRASITP53 group versus all others among 99 patients who received adjuvant chemotherapy (hazard ratio [HR], 1.22; 95% confidence interval [CI], 0.61-2.44; P = .57), 27 stage III patients who received chemo-radiation (HR, 0.87; 95% CI, 0.32-2.38; P = .8), and 63 patients who received palliative chemotherapy (HR, 0.68; 95% CI, 0.31-1.48; P = .33). OS was longer in the WT/WT group compared with any other group (KRAS: HR, 1.87; 95% CI, 1.02-3.43; P = .043; TP53: HR, 2.17; 95% CI, 1.3-3.61; P = .0028; KRASITP53: HR, 2.06; 95% CI, 1.09-3.88; P = .026). No OS difference was seen for KRAS/TP53 compared with the other groups (HR, 1.26; 95% CI, 0.75-2.13; P = .38). Conclusions: There was no significant difference in DFS/PFS between the 4 groups. However, OS was longer for patients with TP53 and KRAS wild-type NSCLC who received chemotherapy for any stage compared with patients with KRAS, TP53 mutation, or double mutant tumors. (C) 2019 Elsevier Inc. All rights reserved.
引用
收藏
页码:E338 / E345
页数:8
相关论文
共 50 条
[41]   The prognostic effect of single and multiple cancer-related somatic mutations in resected non-small-cell lung cancer [J].
Jao, Kevin ;
Tomasini, Pascale ;
Kamel-Reid, Suzanne ;
Korpanty, Gregorz J. ;
Mascaux, Celine ;
Sakashita, Shingo ;
Labbe, Catherine ;
Leighl, Natasha B. ;
Liu, Geoffrey ;
Feld, Ronald ;
Bradbury, Penelope A. ;
Hwang, David M. ;
Pintilie, Melania ;
Tsao, Ming-Sound ;
Shepherd, Frances A. .
LUNG CANCER, 2018, 123 :22-29
[42]   Frequency of EGFR and KRAS mutations in patients with non small cell lung cancer by racial background: Do disparities exist? [J].
Bauml, Joshua ;
Mick, Rosemarie ;
Zhang, Yu ;
Watt, Christopher D. ;
Vachani, Anil ;
Aggarvval, Charu ;
Evans, Tracey ;
Langer, Corey .
LUNG CANCER, 2013, 81 (03) :347-353
[43]   Meta-analysis of the prognostic impact of TP53 co-mutations in EGFR-mutant advanced non-small-cell lung cancer treated with tyrosine kinase inhibitors [J].
Ferrara, Miriam Grazia ;
Belluomini, Lorenzo ;
Smimmo, Annafrancesca ;
Sposito, Marco ;
Avancini, Alice ;
Giannarelli, Diana ;
Milella, Michele ;
Pilotto, Sara ;
Bria, Emilio .
CRITICAL REVIEWS IN ONCOLOGY HEMATOLOGY, 2023, 184
[44]   Efficacy of immunotherapy as second-line or later-line therapy and prognostic significance of KRAS or TP53 mutations in advanced non-small cell lung cancer patients [J].
Liu, Jingya ;
Gao, Jianing .
EUROPEAN JOURNAL OF CANCER PREVENTION, 2023, 32 (06) :590-599
[45]   Role of next generation sequencing-based liquid biopsy in advanced non-small cell lung cancer patients treated with immune checkpoint inhibitors: impact of STK11, KRAS and TP53 mutations and co-mutations on outcome [J].
Pavan, Alberto ;
Bragadin, Andrea Boscolo ;
Calvetti, Lorenzo ;
Ferro, Alessandra ;
Zulato, Elisabetta ;
Attili, Ilaria ;
Nardo, Giorgia ;
Dal Maso, Alessandro ;
Frega, Stefano ;
Menin, Andrea Giovanni ;
Fassan, Matteo ;
Calabrese, Fiorella ;
Pasello, Giulia ;
Guarneri, Valentina ;
Aprile, Giuseppe ;
Conte, PierFranco ;
Rosell, Rafael ;
Indraccolo, Stefano ;
Bonanno, Laura .
TRANSLATIONAL LUNG CANCER RESEARCH, 2021, 10 (01) :202-+
[46]   Oncogenic driver mutations in patients with non-small-cell lung cancer at various clinical stages [J].
Zhou, J. X. ;
Yang, H. ;
Deng, Q. ;
Gu, X. ;
He, P. ;
Lin, Y. ;
Zhao, M. ;
Jiang, J. ;
Chen, H. ;
Lin, Y. ;
Yin, W. ;
Mo, L. ;
He, J. .
ANNALS OF ONCOLOGY, 2013, 24 (05) :1319-1325
[47]   MIR-4507 Targets TP53 to Facilitate the Malignant Progression of Non-small-cell Lung Cancer [J].
Zhao, MengYang ;
Tang, ZiBo ;
Wang, YiJun ;
Ding, JiaoJiao ;
Guo, Ying ;
Zhang, Ning ;
Gao, TianHui .
JOURNAL OF CANCER, 2021, 12 (22) :6600-6609
[48]   Polymorphisms in Apoptosis-Related Genes and TP53 Mutations in Non-Small Cell Lung Cancer [J].
Bae, Eun Young ;
Lee, Eun Jin ;
Kang, Hyo-Gyoung ;
Lee, Shin Yup ;
Jin, Gwang ;
Lee, Won Kee ;
Choi, Jin Eun ;
Jeon, Hyo-Sung ;
Lim, Jeong Ok ;
Lee, Eung Bae ;
Park, Jae Yong .
JOURNAL OF KOREAN MEDICAL SCIENCE, 2011, 26 (11) :1527-1530
[49]   The Effect of Chemotherapeutic Agents on Survival in Metastatic Non-Small-Cell Lung Cancer with KRAS Mutation [J].
Duygulu, Mustafa Emre ;
Yildirim, Atila ;
Ayas, Eyyup ;
Alyildiz, Nese ;
Mungan, Sevdegul Aydin ;
Fidan, Evren .
INDIAN JOURNAL OF MEDICAL AND PAEDIATRIC ONCOLOGY, 2024, 45 (02) :127-133
[50]   Survival outcomes in patients with non-small-cell lung cancer treated with erlotinib [J].
McGrath, Alexandria C. ;
Sandhu, Geeta ;
Walpole, Euan ;
McCaffrey, Elizabeth ;
Hollingworth, Samantha A. .
ANTI-CANCER DRUGS, 2018, 29 (08) :786-790